If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX(1-800-545-5979)
Mounjaro™ (tirzepatide) injection2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
When will tirzepatide be available?
Tirzepatide was FDA approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
See important safety information, including boxed warning, in the attached prescribing information.
Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide 1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D).1
Tirzepatide was FDA approved as an adjunct to diet and exercise to improve glycemic control in adults with T2D on May 13.2
Tirzepatide is expected to be available in the U.S. in the coming weeks.2
Enclosed Prescribing Information
1Mounjaro [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.
2FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes. Press release. Eli Lilly and Company; May 13, 2022. Accessed May 13, 2022. http://lilly.mediaroom.com/2022-05-13-FDA-approves-Lillys-Mounjaro-TM-tirzepatide-injection,-the-first-and-only-GIP-and-GLP-1-receptor-agonist-for-the-treatment-of-adults-with-type-2-diabetes
Date of Last Review: May 13, 2022